An amyloidosis workup is a multi-step diagnostic process that moves from clinical suspicion through blood tests, tissue biopsy, amyloid subtyping, and organ-specific assessments to determine which type of amyloid protein is involved and how far the disease has spread. No single test can diagnose and classify amyloidosis on its own, which is part of why the workup often feels sprawling and why getting to a final answer can take months or longer. A large US study found that the median time from first symptoms to diagnosis was about 2.7 years, with half of patients seeing five or more types of physicians along the way.
Why Amyloidosis Is Hard to Catch Early
Amyloidosis tends to announce itself through symptoms that overlap with far more common conditions. Fatigue, swelling, shortness of breath, numbness in the hands, unexplained weight loss, chronic diarrhea: none of these immediately scream “amyloidosis” to most clinicians. A cross-sectional patient survey found that about 59% of people with AL amyloidosis (the light-chain type) reported a diagnostic delay, with roughly a third experiencing delays longer than 12 months. Around half attributed the delay to a lack of provider awareness.1PubMed. Diagnostic Journeys and Delays in AL Amyloidosis: Insights From a Cross-Sectional Patient Survey Another retrospective analysis of over 1,500 US adults found a median delay of 2.7 years from symptom onset to diagnosis, with high healthcare utilization in the interim.2European Journal of Haematology. Diagnostic delay and characterization of the clinical prodrome in AL amyloidosis among 1523 US adults diagnosed between 2001 and 2019
Certain symptom combinations, though, should raise suspicion. A study of 30 patients with hereditary transthyretin amyloidosis found that every patient had at least one “red flag” at diagnosis, with a median of four. The most common were a family history of neuropathy (70%), early autonomic dysfunction (56%), bilateral carpal tunnel syndrome (50%), and gastrointestinal problems (47%).3PubMed. Red flags in patients with hereditary transthyretin amyloidosis at diagnosis in a non-endemic area of Spain Expert consensus guidelines recommend that general practitioners use a diagnostic algorithm based on these red flags, particularly when cardiac or neurologic symptoms appear alongside gastrointestinal or other systemic complaints.4BMC Family Practice. Avoiding misdiagnosis: expert consensus recommendations for the suspicion and diagnosis of transthyretin amyloidosis for the general practitioner The pattern matters more than any individual symptom: unexplained heart failure in someone who also has neuropathy and carpal tunnel syndrome is a very different picture from heart failure alone.
Blood and Urine Tests for Clonal Disease
Once amyloidosis enters the differential, the first lab step is usually screening for a clonal plasma cell process, because AL amyloidosis (caused by misfolded antibody light chains) is the type that most urgently needs treatment. Three tests form the core panel: serum free light chain (FLC) assay, serum immunofixation electrophoresis, and urine immunofixation electrophoresis. Together they are looking for evidence that the body is overproducing one type of light chain protein.
The serum FLC assay has become a workhorse in this space. One study found abnormal free light chain results in 97% of AL amyloidosis patients at diagnosis.5PubMed. Diagnostic and prognostic utility of the serum free light chain assay in patients with AL amyloidosis A separate study comparing the FLC assay to conventional tests found elevated levels in over 90% of patients with the relevant clonal disease, and that an abnormal ratio between the two light chain types was a reliable diagnostic indicator comparable to older methods like bone marrow staining and immunofixation.6PubMed. Quantitative serum free light chain assay in the diagnostic evaluation of AL amyloidosis
These tests matter not just for diagnosing AL amyloidosis but for ruling it out when transthyretin amyloidosis (ATTR) is suspected. As we’ll see in the cardiac imaging section, interpreting certain nuclear scans correctly depends on knowing whether a clonal process is present.
Tissue Biopsy and Congo Red Staining
A definitive amyloidosis diagnosis still requires tissue proof: a biopsy specimen that lights up with Congo red stain. When Congo red-stained tissue is viewed under polarized light, amyloid deposits produce a distinctive apple-green birefringence. This remains the standard method used in most pathology labs.7PubMed Central. Improving sensitivity of amyloid detection by Congo red stain by using polarizing microscope and avoiding pitfalls The technique has real limitations, though. Subtle deposits can be missed on routine clinical microscopes, and specialized polarized microscopy equipment improves sensitivity considerably over standard setups.8PubMed. An evaluation of Congo red fluorescence for the diagnosis of amyloidosis
Where the biopsy comes from matters. Abdominal fat pad aspiration is the least invasive option and is often tried first, but its sensitivity varies depending on the type of amyloidosis and the organ primarily affected.9PubMed Central. Abdominal Fat Biopsy for the Diagnosis of Cardiac Amyloidosis When amyloidosis primarily involves a specific organ, a biopsy of that organ is more reliable. For gastrointestinal involvement, the duodenum is considered the most reliable diagnostic site.10Journal of Gastroenterology and Hepatology. Amyloidosis for the Gastroenterologist: A Comprehensive Systematic Review of Diagnosis and Management of Gastrointestinal Manifestations For renal involvement, kidney biopsy is the definitive test, particularly when proteinuria appears alongside systemic symptoms like heart failure or neuropathy.11The American Journal of Medicine. Renal Amyloidosis: Clinical Presentation, Diagnosis, and Management – Section: Diagnosis And for cardiac amyloidosis, endomyocardial biopsy remains the gold standard when non-invasive testing is inconclusive.
Amyloid Subtyping With Mass Spectrometry
Confirming that amyloid is present is only half the battle. The type of amyloid protein determines everything about treatment, so misidentifying it can be dangerous. There are more than 30 known amyloid-forming proteins, and while AL and ATTR account for the majority of systemic cases, rarer types like AA (from chronic inflammation), fibrinogen, and apolipoprotein variants also occur. The clinical presentation alone cannot reliably distinguish between them.
Laser microdissection followed by tandem mass spectrometry (usually abbreviated LCM-MS) has become the reference standard for subtyping. The technique works by isolating the amyloid deposits from a biopsy slide under a microscope, then running those proteins through a mass spectrometer to identify exactly what they are. A study from the Mayo Clinic demonstrated that major amyloid types were distinguishable with 100% specificity using this approach.12PubMed Central. Tandem Mass Spectrometry-Based Amyloid Typing Using Manual Microdissection and Open-Source Data Processing A kidney-focused study similarly showed that mass spectrometry could identify the full range of amyloid proteins deposited in the kidney, including several rare types, in a single procedure.13PubMed Central. Laser microdissection and mass spectrometry-based proteomics aids the diagnosis and typing of renal amyloidosis
The practical impact of this step is substantial. One implementation study spanning five years found that proteomic analysis changed the referring clinician’s suspected amyloid subtype in about a quarter of cases.14PubMed Central. Implementation and evaluation of amyloidosis subtyping by laser-capture microdissection and tandem mass spectrometry That means one in four patients would have been pointed toward the wrong treatment without mass spectrometry confirmation. Not all centers have this technology in-house, so biopsy specimens are frequently shipped to specialized labs.
Cardiac Evaluation
The heart is among the organs most commonly affected by amyloidosis, and the degree of cardiac involvement is the single biggest driver of prognosis. The cardiac workup typically involves several complementary tools.
Technetium Bone Scintigraphy
Technetium-99m pyrophosphate (PYP) scanning has transformed the diagnosis of transthyretin cardiac amyloidosis. The radiotracer, originally designed for bone imaging, binds avidly to ATTR amyloid deposits in the heart. An efficient one-hour imaging protocol showed 98% sensitivity and 96% specificity for ATTR cardiac amyloidosis.15Circulation: Cardiovascular Imaging. Efficient 1-Hour Technetium-99 m Pyrophosphate Imaging Protocol for the Diagnosis of Transthyretin Cardiac Amyloidosis In patients who undergo biopsy for confirmation, strongly positive scans (grades 2 and 3) had a sensitivity around 94% and specificity of 89%, with the highest-grade scans reaching 100% specificity.16PubMed Central. Diagnosing Transthyretin Cardiac Amyloidosis by Technetium Tc 99m Pyrophosphate: A Test in Evolution
The catch is that a positive PYP scan does not always mean ATTR. It can occasionally light up in AL amyloidosis too, likely due to calcification of amyloid deposits. That is why expert consensus requires ruling out a clonal plasma cell process with free light chains and immunofixation before a positive PYP scan can be taken as diagnostic of ATTR without biopsy.17PubMed Central. False positive technetium-99m pyrophosphate scintigraphy in a patient with cardiac amyloidosis light chain: Case report One center reported that out of 273 patients evaluated, only 27 needed endomyocardial biopsy, all because they had a monoclonal protein present that made the PYP scan ambiguous.18British Journal of Cardiology. Cardiac technetium-99m pyrophosphate scintigraphy imaging in the evaluation of cardiac amyloidosis: a single-centre experience When no clonal process is found, a strongly positive PYP scan can confirm ATTR cardiac amyloidosis without any tissue biopsy at all.
Cardiac MRI
Cardiac magnetic resonance imaging (CMR) adds different information. Its signature finding is late gadolinium enhancement (LGE), which reflects amyloid infiltration and fibrosis in the heart muscle. In a study of patients with biopsy-proven cardiac amyloidosis, LGE was present in 97% of cases, and its pattern (typically a global, transmural, or subendocardial distribution) correlated with the actual burden of amyloid deposition.19PubMed. Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis CMR can also reveal a characteristic strain pattern: reduced overall squeezing of the heart with relatively preserved function at the apex, a pattern called “relative apical sparing.” This gradient in strain may help distinguish cardiac amyloidosis from other conditions that cause a thickened heart wall, such as hypertrophic cardiomyopathy.20PubMed Central. Patterns of CMR measured longitudinal strain and its association with late gadolinium enhancement in patients with cardiac amyloidosis and its mimics
Cardiac Biomarkers and Staging
Blood tests for cardiac stress proteins serve double duty: they help confirm heart involvement and they stratify how sick the patient is. For AL amyloidosis, the two key markers are troponin (a protein released when heart muscle is damaged) and NT-proBNP (a hormone the heart secretes under pressure). An early staging system showed that patients with both markers elevated (stage III) had a median survival of only 3.5 months, compared to roughly 26 months when both were normal (stage I).21Journal of Clinical Oncology. Serum Cardiac Troponins and N-Terminal Pro-Brain Natriuretic Peptide: A Staging System for Primary Systemic Amyloidosis A revised system added the difference between involved and uninvolved free light chains, creating a four-tier staging system (I through IV) that further refined predictions.22PubMed Central. Revised Prognostic Staging System for Light Chain Amyloidosis Incorporating Cardiac Biomarkers and Serum Free Light Chain Measurements These staging systems guide treatment urgency: a stage IV patient may need more aggressive upfront therapy, while a stage I patient has more room for a measured approach.
Assessing the Kidneys
Kidney involvement shows up most obviously as protein spilling into the urine. In some cases the proteinuria is massive: one case report documented over 20,000 mg of protein in a 24-hour urine collection, well above normal levels of under 150 mg.23PubMed Central. Kidney Biopsy Corner: Amyloidosis Nephrotic-range proteinuria with swelling, particularly in a patient who also has heart failure or neuropathy, is a classic combination that should prompt amyloidosis testing.24The American Journal of Medicine. Renal Amyloidosis: Clinical Presentation, Diagnosis, and Management – Section: Diagnosis
When kidney biopsy is performed, the tissue is not just stained with Congo red for amyloid; it is also examined under electron microscopy for the characteristic fibrillar structure and often sent for mass spectrometry subtyping. Kidney involvement is common in both AL and AA amyloidosis but relatively uncommon in cardiac ATTR, so the presence of significant renal disease already narrows the differential.
Neurological Assessment
Nerve involvement in amyloidosis can range from carpal tunnel syndrome to full-blown polyneuropathy with autonomic failure. A study of 43 consecutive AL amyloidosis patients found that about 35% had apparent neuropathic symptoms, with polyneuropathy in roughly a quarter and autonomic dysfunction in about 19%. But the electrophysiological findings were more widespread: even patients without obvious nerve symptoms showed decreased motor nerve conduction velocities and reduced electrical signals, suggesting subclinical nerve damage.25PubMed. Peripheral nerve involvement in primary systemic AL amyloidosis: a clinical and electrophysiological study Nerve conduction studies and electromyography are standard parts of the workup when neuropathy is suspected, and they help distinguish amyloid neuropathy from other causes of peripheral nerve disease.
For transthyretin amyloidosis specifically, progressive sensorimotor neuropathy starting in the feet and hands is often the initial presentation, especially in hereditary forms. Autonomic symptoms such as orthostatic lightheadedness, alternating constipation and diarrhea, or erectile dysfunction can precede the sensory complaints by years, which helps explain why bilateral carpal tunnel syndrome and early autonomic dysfunction are considered red flags worth investigating further.
AA Amyloidosis and the Inflammatory Connection
Not all amyloidosis stems from a blood cancer or a genetic mutation. AA amyloidosis develops in the setting of chronic inflammation, where the liver continuously produces serum amyloid A (SAA) protein as part of the inflammatory response. Conditions like rheumatoid arthritis, chronic infections, and inflammatory bowel disease are the usual drivers. The workup for suspected AA amyloidosis focuses on identifying and quantifying the underlying inflammatory disease, checking SAA levels, and obtaining tissue confirmation.
Keeping SAA levels low is the goal of treatment, and the evidence suggests it works. A prospective study of 80 patients followed for up to nearly ten years found that amyloid deposits actually regressed in a majority of patients whose SAA stayed consistently under 10 mg/L, and estimated ten-year survival was 90% in that group compared to 40% in those whose SAA stayed higher.26The Lancet. Non-treatment-dependent regression of advanced systemic amyloidosis Targeted anti-inflammatory therapy aimed at normalizing SAA levels can prevent further amyloid deposition and protect the kidneys, which are the organs most often affected in AA disease.27PubMed. Secondary, AA, Amyloidosis
Localized Versus Systemic Disease
Sometimes amyloid is found in a single site, such as the bladder, skin, airways, or breast, without evidence of widespread deposition. Localized amyloidosis is generally far more benign than the systemic forms, but the distinction is not always straightforward. A full workup is still recommended when amyloid turns up in a biopsy specimen to rule out systemic disease or an associated malignancy.28PubMed Central. Rare Diagnosis of Localized Breast Amyloidosis in the Setting of Lymphoplasmacytic Lymphoma That workup typically includes the same serum FLC and immunofixation panel, cardiac biomarkers, 24-hour urine protein, and sometimes imaging to check for organ infiltration. Only when all these come back clean can the amyloid be confidently labeled localized.
Emerging PET Imaging
Positron emission tomography (PET) using amyloid-binding radiotracers is an active area of development. These tracers, some originally designed for brain amyloid imaging in Alzheimer’s research, are being adapted for systemic amyloidosis. A systematic review and meta-analysis of 17 studies found that amyloid PET showed a pooled sensitivity of about 91% and specificity of about 90% for cardiac amyloidosis, with strong overall diagnostic accuracy.29European Heart Journal – Imaging Methods and Practice. Diagnostic value of positron emission tomography using amyloid-binding radiotracers for cardiac amyloidosis: a systematic review and meta-analysis Another meta-analysis of studies evaluating cardiac involvement specifically reported even higher sensitivity but somewhat lower specificity, with one radiotracer (I-124 Evuzamitide) achieving the highest sensitivity and another (C-11 Pittsburgh Compound-B) achieving the best specificity.30PubMed Central. Diagnostic Performance of Positron Emission Tomography in the Assessment of Systemic Amyloidosis: A Systematic Review and Meta-Analysis PET is not yet part of routine clinical practice for systemic amyloidosis, but it may eventually help quantify the total amyloid burden in the body and track whether deposits are shrinking with treatment.
Defining Organ Involvement and Tracking Response
Once the type of amyloidosis is established, the workup shifts to cataloging which organs are involved and to what degree. For AL amyloidosis, internationally agreed-upon consensus criteria define organ involvement based on specific findings: cardiac involvement is flagged by wall thickness on echocardiography or elevated NT-proBNP, renal involvement by proteinuria above a defined threshold, liver involvement by organ enlargement or elevated alkaline phosphatase, and nerve involvement by clinical polyneuropathy or specific nerve conduction abnormalities.31American Journal of Hematology. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis These same criteria also define what counts as a treatment response in each organ, which is critical for monitoring.
For gastrointestinal involvement specifically, symptoms can include early satiety, nausea, diarrhea, constipation, and weight loss, but these are nonspecific enough that endoscopy with biopsy is often needed to confirm amyloid infiltration of the GI tract. When GI amyloidosis is suspected, duodenal biopsy is considered the most reliable site.32Journal of Gastroenterology and Hepatology. Amyloidosis for the Gastroenterologist: A Comprehensive Systematic Review of Diagnosis and Management of Gastrointestinal Manifestations Liver involvement in amyloidosis may be detectable by elastography (FibroScan), which measures liver stiffness and could offer a non-invasive way to track hepatic amyloid over time.
What Often Goes Wrong in the Diagnostic Process
The workup described above sounds systematic, but in practice it frequently gets derailed. The biggest problem is that amyloidosis simply isn’t on a clinician’s radar when a patient first walks in with fatigue, swelling, or tingling hands. Data presented at the 2025 COMy congress showed a median delay of six months from initial symptoms to diagnosis, with certain symptoms like bilateral carpal tunnel syndrome and arthritis linked to delays as long as 156 months.33European Medical Journal. COMy 2025: Diagnosis Delays in Amyloid Light-Chain Amyloidosis Cardiologists and nephrologists, who you might expect to catch these cases, established the diagnosis in only about 16% and 14% of cases, respectively.34PubMed. Diagnostic Journeys and Delays in AL Amyloidosis: Insights From a Cross-Sectional Patient Survey
Another common pitfall is incomplete subtyping. As noted above, a quarter of cases had their amyloid subtype changed after mass spectrometry analysis. Relying on clinical features or immunohistochemistry alone can lead to misclassification, which matters when the treatments for AL and ATTR amyloidosis are completely different: chemotherapy for AL, and stabilizer drugs or gene-silencing therapies for ATTR. Starting the wrong treatment based on a wrong subtype is a real and avoidable error. If you or someone you know is diagnosed with amyloidosis and has not had mass spectrometry subtyping performed, it is reasonable to ask whether the biopsy specimen can be sent to a reference lab for that analysis.